Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Rad-G is a rugged, portable, handheld Masimo SET Measure-through Motion and Low Perfusion pulse oximeter and noninvasive respiration rate monitor
Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)
The campaign aims to increase awareness about Tuberculosis as a curable disease and promote early diagnosis.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
It is estimated that one-third of our country’s population has some form of these disorders
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
Subscribe To Our Newsletter & Stay Updated